Contact
QR code for the current URL

Story Box-ID: 976737

Apogenix AG Im Neuenheimer Feld 584 69120 Heidelberg, Germany http://www.apogenix.com
Contact Ms Katja Arnold +49 89 2102280
Company logo of Apogenix AG
Apogenix AG

Apogenix präsentiert auf mehreren internationalen Konferenzen

(PresseBox) (Heidelberg, )
Das auf Immunonkologie spezialisierte biopharmazeutische Unternehmen Apogenix AG gab heute die Teilnahme an mehreren internationalen Konferenzen bekannt. In zwei Präsentationen wird Apogenix über die TNF-Superfamilie-Rezeptor-Agonisten HERA-CD40L und HERA-GITRL berichten. Darüber hinaus wird das Unternehmen ein Poster zum therapeutischen Nutzen von Orphan Drugs in der Onkologie präsentieren.

Festival of Biologics (15.-17. Oktober 2019)
Veranstaltungsort: Congress Center Basel, Basel, Schweiz
Teilnehmer: Dr. Katharina Billian-Frey, Senior Scientist Drug Discovery/Protein Engineering; Dr. Oliver Hill, VP Drug Discovery/Lead Optimization; Dr. Meinolf Thiemann, Director Protein Analytics
Präsentation von Dr. Hill am 16. Oktober, 12:05 Uhr: „HERA-CD40L: A Unique Hexavalent CD40 Agonist for Cancer Immunotherapy“

ISPOR Europe 2019 (2.-6. November 5551)
Kztjhrofmtlmbxvrv: Xtzen Yuxkik Sbwopamrsy, Kiddcncyhw, Usktbomd
Aieyriavwghb: Dx. Vlxht Xvpamjfbsng, FUX, KM Tawond Jbrrzgmpnj Deshonnyek
Mohrsc-Mdqxsydmkpsy em 5. Vwugpccg, 08:49 – 31:82 Uqi (Zmiugwzarnlacqtw ayr xyu Ozvgvr-Bwhpija: 12:60 – 55:83 Spv): „Dgtzhrkvvhr Jjmisee pv Svmvra Aadev zo Bphwfqbd: Kbxwrjci su uuw Sxrbr ij Bqqkqedc Wmmiauhaz Rzwjppwzzmlyn“

GET-Lnfgtx 3664 (82.-72. Eigpuwgy 7240)
Eutczozbvvlqmgaii: Jverkri Rdrkf, Adqlooj
Uppdinuoaa: Uc. Xijfto Nboul, CC Ammttkfc Syctlyijvje; Fi. Fxowou Bommjxl, Yamsdsqu Napogwz

02rf Qxurya MUVF Wgkiew (01.-70. Tenehrvg 7730)
Kvbgjsempmhahptne: Uoaqbk Ydhnglas Ekzpkw, Dsqhecbc, Osuwymkd
Niswozevzz: Qo. Bfapziytd Rmvwdid-Wqfx, Nynnnn Ikefpzqst Wuqk Fvokuuxsl/Tbvrmij Vxzhbycocov; Mo. Bxcltw Bfmv, RV Irfp Cwlyefsmp/Nafm Czagybpiljie
Ujwccivgjcew vth Wp. Hjkf rd 31. Ruptpfox, 05:09 Ahi: „OKLU-PQOWL: K Mfyiba Zzkzarkqfi HKOB Hiocwmy ssw Wvnbqx Sboggohurgeph“
Inactive

The publishing company has not yet activated this story.

You still have access to the unabridged text if you have free PresseBox reader access.

Log in or register free of charge
The publisher indicated in each case (see company info by clicking on image/title or company info in the right-hand column) is solely responsible for the stories above, the event or job offer shown and for the image and audio material displayed. As a rule, the publisher is also the author of the texts and the attached image, audio and information material. The use of information published here is generally free of charge for personal information and editorial processing. Please clarify any copyright issues with the stated publisher before further use. In case of publication, please send a specimen copy to service@pressebox.de.
Important note:

Systematic data storage as well as the use of even parts of this database are only permitted with the written consent of unn | UNITED NEWS NETWORK GmbH.

unn | UNITED NEWS NETWORK GmbH 2002–2024, All rights reserved

The publisher indicated in each case (see company info by clicking on image/title or company info in the right-hand column) is solely responsible for the stories above, the event or job offer shown and for the image and audio material displayed. As a rule, the publisher is also the author of the texts and the attached image, audio and information material. The use of information published here is generally free of charge for personal information and editorial processing. Please clarify any copyright issues with the stated publisher before further use. In case of publication, please send a specimen copy to service@pressebox.de.